Find More Contacts for Signum Biosciences
Protected Content
Admin, Admin, Finance, CFO, Financial Officer
Non-Management, Executive Finance, Management
3 emails found 1 phone number found
View contacts for Signum Biosciences to access new leads and connect with decision-makers.
View All Contacts
  • Company Type For Profit
  • Contact Email info@signumbio.com
  • Phone Number 7323298344

Signum Biosciences is a private biotechnology company dedicated to developing small-molecule therapeutics derived from its Signal Transduction Modulation (STM) platform to modulate signal transduction imbalances. Through research on protein networks that control biological systems, Signum is developing therapeutic agents for several skin

conditions, Alzheimer's, Parkinson's, asthma and COPD. Signum's STM technology provides many opportunities for the development of novel consumer products and pharmaceutical candidates.

Lists Featuring This Company

Boulder Companies
2,946 Number of Organizations • $11.7B Total Funding Amount • 1,802 Number of Investors
Private Colorado Companies (Top 10K)
9,981 Number of Organizations • $66.1B Total Funding Amount • 5,962 Number of Investors
Colorado Companies With Less Than $10M in Revenue (Top 10K)
9,800 Number of Organizations • $20B Total Funding Amount • 3,670 Number of Investors
Biotechnology Companies With More Than $1M in Revenue (Top 10K)
10,000 Number of Organizations • $804.9B Total Funding Amount • 36,947 Number of Investors

Frequently Asked Questions

Where is Signum Biosciences's headquarters? Signum Biosciences is located in Boulder, Colorado, United States.Who invested in Signum Biosciences? Signum Biosciences is funded by NJEDA.How much funding has Signum Biosciences raised to date? Signum Biosciences has raised .When was the last funding round for Signum Biosciences? Signum Biosciences closed its last funding round on Nov 15, 2013 from a Grant round.Who are Signum Biosciences's competitors? Alternatives and possible competitors to Signum Biosciences may include Gritstone bioCarisma Therapeutics, and Interius BioTherapeutics.